Division of Leo Pharma AS
Latest From Peplin Ltd.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
Newly approved plant-based gel works in just a few days of treatment, rather than the weeks required for some competitors.
Dermira Inc, a new company focusing on the dermatology arena including an early-stage acne therapy candidate, has raised $42 million in a Series A round, which includes existing investor Bay City Capital, along with New Enterprise Associates and Canaan Partners. In conjunction with the fund raising, Dermira has acquired the dermatology company Velocor Therapeutics for an undisclosed sum, and it will continue to seek out other dermatological assets for licensing or acquisition.
- Drug Delivery
- Therapeutic Areas
- Peplin Biotech Ltd.
- Parent & Subsidiaries
- Leo Pharma AS
- Senior Management
Michael Aldridge, CEO
Philip Moody, VP, Fin. & Operations & CFO
Arthur P Bertolino, MD, PhD, VP, Medical Affairs & CMO
George Mahaffey, Chief Comm. Officer & VP, Sales & Mktg.
- Contact Info
Phone: (61) 7 3250 1200
1 Breakfast Creek Rd.
Newstead, QLD 4006
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.